All News

Ambrisentan (Letairis) from Gilead Sciences, Inc. has been approved by the FDA for patients with PAH (WHO Group 1) with WHO Functional Class II or III symptoms.

Patient takes tramadol 100 mg every six hours for chronic back pain; other medications include two lithium carbonate, extended release tablets, ziprasidone, temazepam, and trazodone.

Researchers at the American Society of Clinical Oncology meeting stressed that treatment more targeted, with fewer side effects, than before - and cancer deaths are down for the first time in 70 years.

At ASHP's 2007 summer meeting, the house of delegates approved a resolution calling for all pharmacists to complete a residency as a prerequisite to direct patient care by the year 2020.

Walgreen Co. has reached an agreement to purchase specialty pharmacy operator Option Care Inc. for about $850 million. Option Care, based in Buffalo Grove, Ill., provides a full spectrum of specialty-pharmacy and home-infusion services

According to CMS, its partner Argus Health Systems will begin building a network of pharmacies and the program will work similarly to third-party insurance?providing pharmacists with specific instructions on how to handle prescriptions for victims of disasters.

The Convenient Care Association (CCA), the industry trade group that represents retail clinics, recently met to discuss a response to American Medical Association concerns that the clinics represent a conflict of interest.

The purpose of the agreement is to make it possible for members of PPOK to gain entry into the home infusion and specialty pharmacy market with a Vital Care franchise.

s of Aug. 1, patients with cystic fibrosis and Pseudomonas aeruginosa infection who have limited treatment options and are at risk for becoming worse off can access Gilead Sciences' investigational drug aztreonam lysine for inhalation.